Clinical Trial Detail

NCT ID NCT01796171
Title A Phase I/II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Nordic Nanovector
Indications

marginal zone B-cell lymphoma

CLL/SLL

follicular lymphoma

mantle cell lymphoma

lymphoplasmacytic lymphoma

Therapies

Lilotomab

Betalutin

Rituximab

Age Groups: senior adult

No variant requirements are available.